Cover Image
市場調查報告書

眼科用醫藥品的全球市場 2016-2026年的預測:乾眼症、青光眼、視網膜疾病、過敏、發炎及感染疾病治療藥的主要企業的展望

Ophthalmic Drugs Market Forecast 2016-2026: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs

出版商 Visiongain Ltd 商品編碼 239210
出版日期 內容資訊 英文 334 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
眼科用醫藥品的全球市場 2016-2026年的預測:乾眼症、青光眼、視網膜疾病、過敏、發炎及感染疾病治療藥的主要企業的展望 Ophthalmic Drugs Market Forecast 2016-2026: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs
出版日期: 2016年07月15日 內容資訊: 英文 334 Pages
簡介

本報告提供全球眼科用醫藥品的市場相關調查,主要的各眼科疾病種類的收益預測,目前主要藥物,主要藥物的收益及市場佔有率預測,開發平台趨勢,主要國家的分析,市場影響因素分析,主要企業簡介等,詳細內容彙整。

第1章 報告概要

第2章 簡介:眼科用醫藥品

  • 醫藥品產業概要
  • 人的眼睛:結構性纖細且功能性複雜的內臟器官
  • 眼精疾病的全球醫療費負擔
  • 眼科用醫藥品:市場區隔
  • 青光眼:失明的主要原因
  • 老年性黃斑部病變 (AMD)
  • 糖尿病視網膜病變 (DR)
  • 眼科過敏、過敏性結膜炎
  • 眼科發炎性疾病
  • 眼科感染疾病
  • 乾眼症症候群
  • 臨床試驗的階段
  • 眼科用醫藥品:本報告的市場定義

第3章 全球眼科用醫藥品市場

  • 全球眼科用醫藥品市場:市場概要
  • 全球眼科用醫藥品市場分類
  • 全球眼科用醫藥品市場
  • 全球眼科用醫藥品市場:市場預測
  • 眼科用醫藥品:市場佔有率的變化,各部門

第4章 視網膜疾病治療藥市場:市場分析、預測

  • 視網膜疾病治療藥市場上主要產品
  • 視網膜疾病:市場趨勢、發展
  • 視網膜疾病治療藥:市場預測
  • 視網膜疾病治療主要的醫藥品
  • Eylea (aflibercept) Regeneron/Bayer/參天製藥)
  • Lucentis (ranibizumab) Roche/Novartis
  • Avastin (bevacizumab) Roche
  • Visudyne (verteporfin) Valeant/Novartis
  • Jetrea (ocriplasmin) ThromboGenics/Novartis
  • 其他

第5章 眼科過敏,發炎及感染疾病治療藥市場:市場分析、預測

  • 主要產品
  • 市場趨勢、發展
  • 市場預測
  • 主要的醫藥品
  • Patanol、Pataday (olopatadine) - Alcon (Novartis)
  • Vigamox (moxifloxacin) - Alcon (Novartis)
  • TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
  • Cravit (levofloxacin) - 參天製藥
  • Acular (ketorolac) - Allergan (Actavis)
  • AzaSite (azithromycin) - Akorn
  • 其他眼科過敏,發炎及感染疾病治療藥:銷售額預測

第6章 青光眼治療藥市場:市場分析、預測

  • 青光眼治療藥:市場概要
  • 青光眼治療藥:市場趨勢、發展
  • Simbrinza:不用最初的β- 阻斷劑的混合藥
  • 青光眼治療藥:市場預測
  • 青光眼治療主要的治療藥
  • Lumigan、Ganfort - Allergan (Actavis)
  • Xalatan、Xalacom (latanoprost) - Pfizer
  • Travatan/Travatan Z、DuoTrav (travoprost, Novartis)
  • Alphagan/Alphagan P、Combigan (brimonidine) - Allergan
  • Trusopt、Cosopt/Cosopt PF (dorzolamide) - Merck/ Santen
  • Azopt (brinzolamide) - Novartis
  • Zioptan (tafluprost) - Akorn
  • 其他

第7章 乾眼症治療藥市場:市場分析、預測

  • 乾眼症治療藥:市場概要
  • 乾眼症治療藥:市場趨勢、發展
  • 乾眼症治療藥:市場預測
  • 乾眼症治療藥的主要藥物
  • Restasis (ciclosporin) - Allergan (Actavis)
  • Refresh Brand Products - Allergan (Actavis)
  • Hyalein (hyaluronic acid) - 參天製藥
  • Diquas (diaquafosol) - 參天製藥
  • 其他乾眼症治療藥:銷售額預測
  • 其他眼科治療藥

第8章 眼科治療藥的主要國家市場

  • 眼科治療藥市場:各地區
  • 主要國家市場:預測
  • 地區的眼科治療藥市場:分析、預測
  • 美國:最大的眼科治療藥市場
  • 歐盟5國
    • 市場預測
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
  • 日本
  • 中國
  • 巴西
  • 俄羅斯
  • 印度
  • 其他

第9章 眼科治療藥市場主要企業

  • 眼科治療藥:不斷變化的市場形勢
  • 眼科治療藥市場上的主要企業
  • Novartis (Alcon)
  • Regeneron
  • Allergan (Actavis)
  • Roche
  • Valeant
  • 參天製藥
  • Bayer
  • Pfizer
  • 千壽製藥

第10章 眼科治療藥:研發產品線

  • 眼科治療藥的開發平台:視網膜疾病的集中性開發的配合措施
  • 視網膜疾病治療藥:開發平台
  • 視網膜疾病:近幾年被開始的領域
  • 視網膜疾病的第三階段開發中的治療藥
  • 視網膜疾病的第二階段開發中的治療藥
  • 視網膜疾病的第一階段開發中的治療藥
  • 眼科過敏、發炎及感染疾病治療藥狀況:開發平台
  • 眼科過敏、發炎及感染疾病的第三階段開發中的治療藥
  • 眼科過敏、發炎及感染疾病的第二階段開發中的治療藥
  • 眼科過敏、發炎及感染疾病的第一階段開發中的治療藥
  • 青光眼的治療藥:開發平台
  • 青光眼的第2、3階段開發中的治療藥
  • 青光眼的第一階段開發中的治療藥
  • 乾眼症治療藥:開發平台
  • 乾眼症的第三階段開發中的治療藥
  • 乾眼症的第二階段開發中的治療藥
  • 其他開發中的眼科疾病治療藥

第11章 眼科治療藥市場定性分析

  • 眼科治療藥的市場影響因素
  • 全球眼科治療藥市場SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • 波特的五力分析

第12章 結論

  • 目前市場、市場預測概要
  • 眼科治療藥的主要部門
  • 眼科治療藥市場上的主要地區
  • 眼科治療藥市場上的主要企業
  • 眼科治療藥的前景

第13章 用語

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0128

What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.

Our 334-page report provides 238 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:

  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs

image1

The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:

  • Novartis
  • Regeneron
  • Allergan
  • Roche
  • Valeant
  • Santen
  • Bayer
  • Pfizer
  • Senju

The report also includes revenue forecasts to 2026 for the following ophthalmic drugs:

  • Eylea
  • Lucentis
  • Avastin
  • Visudyne
  • Jetrea
  • Pataday
  • Vigamox
  • Patanol
  • TobraDex
  • Cravit
  • AzaSite
  • Acular
  • Lumigan and Ganfort
  • Xalatan/Xalacom
  • Travatan/Travatan Z and DuoTrav
  • Alphagan/Alphagan P and Combigan
  • Azopt
  • Trusopt
  • Zioptan
  • Cosopt
  • Tapros/Taflotan
  • Restasis
  • Refresh
  • Hyalein
  • Diquas

Leading companies and potential for market growth

Retinal disorder drugs will remain the leading ophthalmic submarket to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of leading companies, including these:

  • Novartis
  • Regeneron
  • Allergan
  • Roche
  • Valeant
  • Santen
  • Bayer
  • Pfizer
  • Senju

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Revenue forecasts to 2016 for ophthalmic drugs marketed by the company
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the ophthalmic drugs industry?

Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Ophthalmic Drugs Market Forecast 2016-2026 report helps you

In summary, our 334-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.
  • Revenue forecasts to 2026 for 25 leading drugs - discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Avastin, Visudyne, Jetrea, Pataday, Vigamox, Patanol, TobraDex, Cravit, AzaSite, Acular, Lumigan and Ganfort, Xalatan/Xalacom, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Azopt, Trusopt, Zioptan, Cosopt, Tapros/Taflotan, Restasis, Refresh, Hyalein and Diquas
  • Revenue forecasts to 2026 for the 9 leading companies in the market - discover the industry's prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer and Senju
  • Assessment of 50 pipeline products - analysis of clinical trial progress and drug candidate potential across all ophthalmic indications
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

Table of Contents

1. Report Overview

  • 1.1 Global Ophthalmic Drugs: Market Overview
  • 1.2 Global Ophthalmic Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered By This Analytical Report
  • 1.6 Who Is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction to Ophthalmic Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1 Ophthalmic Treatments - An Industry Overview
  • 2.2 The Human Eyes - Structurally Delicate And Functionally Intricate Organs
  • 2.3 The Global Burden Of Eye Disease
  • 2.4 Ophthalmic Drugs: Market Segmentation
  • 2.5 Glaucoma: A Major Cause Of Vision Loss
    • 2.5.1 A Classification Of Glaucoma
      • 2.5.1.1 Primary Open-Angle Glaucoma
      • 2.5.1.2 Acute Angle-Closure Glaucoma
      • 2.5.1.3 Congenital Glaucoma
      • 2.5.1.4 Secondary Glaucoma
      • 2.5.1.5 Normal-Tension Glaucoma
      • 2.5.1.6 Ocular Hypertension
    • 2.5.2 Risk Factors For Glaucoma
    • 2.5.3 Diagnosis Of Glaucoma
    • 2.5.4 Drug Treatment Of Glaucoma
    • 2.5.5 Laser Treatment And Surgery For Glaucoma
  • 2.6 Age-Related Macular Degeneration (AMD)
    • 2.6.1 Dry (non-exudative) AMD
    • 2.6.2 Wet (exudative) AMD
    • 2.6.3 Risk Factors For AMD
    • 2.6.4 Diagnosis of AMD
    • 2.6.5 Treatment of AMD
  • 2.7 Diabetic Retinopathy (DR)
    • 2.7.1 Diagnosis Of Diabetic Retinopathy
    • 2.7.2 Treatment Of Diabetic Retinopathy
  • 2.8 Ocular Allergy And Allergic Conjunctivitis
    • 2.8.1 Diagnosis Of Ocular Allergy
    • 2.8.2 Treatment Of Ocular Allergy
  • 2.9 Ocular Inflammatory Disease
    • 2.9.1 Treatment Of Ocular Inflammatory Disease
  • 2.10 Eye Infections
    • 2.10.1 Treatment Of Eye Infections
  • 2.11 Dry Eye Syndrome
    • 2.11.1 Treatment of Dry Eye Syndrome
  • 2.12 Phases of Clinical Trials
  • 2.13 Ophthalmic Drugs: Market Definition In This Report

3. The Global Ophthalmic Drugs Market, 2016-2026

  • 3.1 The Global Ophthalmic Drugs Market: Market Overview
  • 3.2 Categorisation of the Global Ophthalmic Drugs Market
  • 3.3 The Global Ophthalmic Drugs Market In 2015
  • 3.4 The Global Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2016-2026

4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2016-2026

  • 4.1 Leading Products in the Retinal Disorder Drugs Market, 2015
  • 4.2 Retinal Disorders: Market Trends And Developments, 2016
    • 4.2.1 The Rise And Rise Of Eylea
    • 4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
    • 4.2.3 How Likely Is Avastin's Expansion Into Age-Related Macular Degeneration?
    • 4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
    • 4.2.5 Drug/Device Combination Products Entering The Market
    • 4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
  • 4.3 Retinal Disorder Drugs: Market Forecast 2016-2026
    • 4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2016-2026
  • 4.4 Leading Drugs For The Treatment Of Retinal Disorders
  • 4.5 Eylea (aflibercept) - Regeneron/ Bayer/ Santen
    • 4.5.1 Recent Approvals For Eylea
    • 4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
    • 4.5.3 Eylea: Sales Forecast 2016-2026
    • 4.5.4 Possible Combination Therapies Involving Eylea
  • 4.6 Lucentis (ranibizumab) - Roche/ Novartis
    • 4.6.1 Lucentis: Sales Forecast 2016-2026
    • 4.6.2 Less Frequent Dosing Approved In US For Lucentis
    • 4.6.3 New Indications For Lucentis
    • 4.6.4 Possible Combination Therapy Involving Lucentis
  • 4.7 Avastin (bevacizumab) - Roche
    • 4.7.1 Avastin: Sales Forecast 2016-2026
    • 4.7.2 Compounding Pharmacies And Safety Risks
  • 4.8 Visudyne (verteporfin) - Valeant/ Novartis
    • 4.8.1 Visudyne: Sales Forecast 2016-2026
  • 4.9 Jetrea (ocriplasmin) - ThromboGenics/ Novartis
    • 4.9.1 Jetrea: Recent Sales Performance
    • 4.9.2 Clinical Study Plans For Jetrea
    • 4.9.3 Jetrea: Sales Forecast 2016-2026
    • 4.9.4 Possible Acquisition Move On ThromboGenics
    • 4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
  • 4.10 Other Retinal Disorder Drugs
    • 4.10.1 Iluvien (fluocinolone implant) - Alimera Sciences
    • 4.10.2 Ozurdex (dexamethasone implant) - Allergan
    • 4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2016-2026

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2016-2026

  • 5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2015
  • 5.2 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2016
    • 5.2.1 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
    • 5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
  • 5.3 Allergic, Inflammatory And Infective Drugs: Market Forecast 2016-2026
    • 5.3.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2016-2026
  • 5.4 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
  • 5.5 Patanol And Pataday (olopatadine) - Alcon (Novartis)
    • 5.5.1 Pataday: Sales Forecast 2016-2026
    • 5.5.2 Impending Generic Competition For Patanol And Pataday
    • 5.5.3 Approval Of Pazeo Solution
    • 5.5.4 Patanol: Sales Forecast 2016-2026
  • 5.6 Vigamox (moxifloxacin) - Alcon (Novartis)
    • 5.6.1 Intensifying Competition And Generics Drug Challenge To Vigamox
    • 5.6.2 Moxeza: A Next-Generation Form of Vigamox
    • 5.6.3 Vigamox: Sales Forecast 2016-2026
  • 5.7 TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
    • 5.7.1 The Development And Commercialisation Of TobraDex ST
    • 5.7.2 TobraDex: Sales Forecast 2016-2026
  • 5.8 Cravit (levofloxacin) - Santen
    • 5.8.1 Cravit: Sales Forecast 2016-2026
  • 5.9 Acular (ketorolac) - Allergan (Actavis)
    • 5.9.1 5.9.1 Acular: Sales Forecast 2016-2026
  • 5.10 AzaSite (azithromycin) - Akorn
    • 5.10.1 AzaSite: Sales Forecast 2016-2026
  • 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2016-2026

6. Glaucoma Drugs Market: Market Analysis And Forecast 2016-2026

  • 6.1 Glaucoma Drugs: Market Overview
    • 6.1.1 Leading Products In The Glaucoma Drugs Market, 2015
  • 6.2 Glaucoma Drugs: Market Trends And Developments, 2016
    • 6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
    • 6.2.2 Preservative-Free Formulation Trends
    • 6.2.3 Innovation In Treatments For Glaucoma
  • 6.3 Simbrinza: First Beta-Blocker-Free Combination
  • 6.4 Glaucoma Drugs: Market Forecast 2016-2026
    • 6.4.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2016-2026
  • 6.5 Leading Drugs For The Treatment Of Glaucoma
  • 6.6 Lumigan And Ganfort (bimatoprost) - Allergan (Actavis)
    • 6.6.1 Lumigan And Ganfort: Sales Forecast 2016-2026
  • 6.7 Xalatan And Xalacom (latanoprost) - Pfizer
    • 6.7.1 Xalatan/Xalacom: Sales Forecast 2016-2026
  • 6.8 Travatan/Travatan Z And DuoTrav (travoprost) - Novartis
    • 6.8.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2016-2026
  • 6.9 Alphagan/Alphagan P And Combigan (brimonidine) - Allergan
    • 6.9.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2016-2026
  • 6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) - Merck/ Santen
    • 6.10.1 Divestment Agreement With Santen And Akorn
    • 6.10.2 Trusopt: Sales Forecast 2016-2026
    • 6.10.3 Cosopt And Cosopt PF: Sales Forecast 2016-2026
  • 6.11 Azopt (brinzolamide) - Novartis
    • 6.11.1 Azopt: Sales Forecast 2016-2026
  • 6.12 Tapros (tafluprost) - Santen
    • 6.12.1 Tapros: Sales Forecast 2016-2026
  • 6.13 Zioptan (tafluprost) - Akorn
    • 6.13.1 Zioptan: Sales Forecast 2016-2026
  • 6.14 Other Glaucoma Drugs: Sales Forecast 2016-2026

7. Dry Eye Drugs Market: Market Analysis And Forecast 2016-2026

  • 7.1 Dry Eye Drugs: Market Overview
    • 7.1.1 Leading Products In The Dry Eye Drugs Market, 2015
  • 7.2 Dry Eye Drugs: Market Trends And Developments, 2016
    • 7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
    • 7.2.2 Intensifying Research Focused On Dry Eye
    • 7.2.3 Improving Diagnostic Tools
  • 7.3 Dry Eye Drugs: Market Forecast 2016-2026
    • 7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2016-2026
  • 7.4 Leading Drugs For The Treatment Of Dry Eye
  • 7.5 Restasis (ciclosporin) - Allergan (Actavis)
    • 7.5.1 Restasis - Generic launch in 2016?
    • 7.5.2 Restasis: Sales Forecast 2016-2026
  • 7.6 Refresh Brand Products - Allergan (Actavis)
    • 7.6.1 Refresh Brand Products: Sales Forecast 2016-2026
  • 7.7 Hyalein (hyaluronic acid) - Santen
    • 7.7.1 Hyalein: Sales Forecast 2016-2026
  • 7.8 Diquas (diaquafosol) - Santen
    • 7.8.1 Diquas: Sales Forecast 2016-2026
  • 7.9 Other Dry Eye Drugs: Sales Forecast 2016-2026
  • 7.10 Other Ophthalmic Drugs
    • 7.10.1 Hetlioz (tasimelteon) - Vanda Pharmaceuticals
    • 7.10.2 Hetlioz: Sales Forecast 2016-2026

8. Leading National Markets For Ophthalmic Drugs, 2016-2026

  • 8.1 The Ophthalmic Drugs Market By Region
    • 8.1.1 The Global Distribution Of Ophthalmic Drugs In 2015
  • 8.2 Leading National Markets: Forecast 2016-2026
    • 8.2.1 Changing Market Shares By Region, 2016-2026
  • 8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2016-2026
  • 8.4 United States: The Largest Ophthalmic Drugs Market
    • 8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
    • 8.4.2 US Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 8.5 EU5
    • 8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
      • 8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2016-2026
    • 8.5.2 Germany
      • 8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2016-2026
    • 8.5.3 France
      • 8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2016-2026
    • 8.5.4 UK
      • 8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2016-2026
      • 8.5.4.2 Brexit - Increased Uncertainty May Affect the UK Ophthalmic Drug Market
    • 8.5.5 Italy
      • 8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2016-2026
    • 8.5.6 Spain
      • 8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 8.6 Japan
    • 8.6.1 The Cost Of Treatment In Japan
    • 8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
    • 8.6.3 Japanese Ophthalmic Drugs Market Forecast 2016-2026
  • 8.7 China
    • 8.7.1 Expansion Of Healthcare Coverage and Reimbursement in China
    • 8.7.2 Price Controls And The Anhui Model
    • 8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 8.8 Brazil
    • 8.8.1 How Will Brazil's Growing Healthcare Influence Ophthalmic Drugs
    • 8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 8.9 Russia
    • 8.9.1 How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 8.10 India
    • 8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
    • 8.10.2 India's Expansion Of Healthcare Provision
    • 8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2016-2026
  • 8.11 Rest of the World
    • 8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2016-2026

9. Leading Companies in the Ophthalmic Drugs Market, 2016-2026

  • 9.1 Ophthalmic Drugs - A Changing Market Landscape
  • 9.2 Leading Companies In The Ophthalmic Drugs Market, 2015
    • 9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2016-2026
    • 9.2.2 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2016-2026
  • 9.3 Novartis (Alcon)
    • 9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2015
    • 9.3.2 Novartis: Sales Forecast 2016-2026
    • 9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016
    • 9.3.4 Novartis: Recent Developments
      • 9.3.4.1 Novartis Restructures Following Strategic Review
      • 9.3.4.2 Novartis Licenses Ophthotech's Fovista
  • 9.4 Regeneron
    • 9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
    • 9.4.2 Regeneron: Recent Developments
      • 9.4.2.1 Expanding Indications For Eylea
      • 9.4.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
    • 9.4.3 Regeneron: Sales Forecast 2016-2026
    • 9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
  • 9.5 Allergan (Actavis)
    • 9.5.1 Allergan: Ophthalmic Drugs Portfolio
    • 9.5.2 Allergan: Recent Developments
      • 9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
      • 9.5.2.2 How Real Is The Threat Of Generic Restasis?
      • 9.5.2.3 Valeant's Attempted Takeover Squashed By Actavis Bid
    • 9.5.3 Allergan: Sales Forecast 2016-2026
    • 9.5.4 Allergan: Ophthalmic Drugs Development Pipeline, 2016
  • 9.6 Roche
    • 9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016
      • 9.6.1.1 Lucentis: US Sales Forecast 2016-2026
    • 9.6.2 Roche: Sales Forecast 2016-2026
    • 9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016
  • 9.7 Valeant
    • 9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
    • 9.7.2 Valeant: Recent Developments
      • 9.7.2.1 Valeant's Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
    • 9.7.3 Valeant: Sales Forecast 2016-2026
    • 9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016
    • 9.7.5 Valeant: Difficult End to 2015 Leads to Uncertainty About Company Future
  • 9.8 Santen
    • 9.8.1 Santen: Ophthalmic Drugs Portfolio, 2015
    • 9.8.2 Santen: Recent Developments
    • 9.8.2.1 Santen Acquires Novagali Pharma
    • 9.8.2.2 Santen Acquires Merck's Ophthalmic Drugs Portfolio
    • 9.8.3 Santen: Sales Forecast 2016-2026
    • 9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016
  • 9.9 Bayer
    • 9.9.1 Bayer: Ophthalmic Drugs Portfolio
    • 9.9.2 Bayer: Sales Forecast 2016-2026
  • 9.10 Pfizer
    • 9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2016
      • 9.10.1.1 Xalatan/Xalacom - Pfizer's Leading Ophthalmic Products
      • 9.10.1.2 Macugen - Valeant/Pfizer
    • 9.10.2 Pfizer: Recent Developments
      • 9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
      • 9.10.2.2 Pfizer Attempts Merger with Allergan
    • 9.10.3 Pfizer: Sales Forecast 2016-2026
    • 9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2016
  • 9.11 Senju
    • 9.11.1 Senju: Ophthalmic Drugs Portfolio
    • 9.11.2 Senju: Sales Forecast 2016-2026
    • 9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016
      • 9.11.3.1 Y 39983 (SNJ 1656)
      • 9.11.3.2 Difluprednate (SJE-2079)

10. Ophthalmic Drugs: Research And Development Pipeline, 2016-2026

  • 10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
  • 10.2 Drugs For Retinal Disorders: Development Pipeline, 2016
    • 10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
  • 10.3 Retinal Disorders: Filed or Recently Launched
    • 10.3.1 Compaq Sipp (conbercept) - Chengdu Kanghong Pharmaceutical
    • 10.3.2 Lipidil (fenofibrate) - Abbott
    • 10.3.3 Iluvien (fluocinolone) - Alimera Sciences
  • 10.4 Drugs In Phase 3 Development For Retinal Disorders
    • 10.4.1 AGN150998 And MP0260 (Anti-VEGF DARPins) - Allergan
    • 10.4.2 Fovista and Zimura - Ophthotech Corporation
    • 10.4.3 Lampalizumab (anti-Factor D Fab) - Roche
    • 10.4.4 MC-1101 (hydralazine) - MacuCLEAR
    • 10.4.5 Squalamine (anti-angiogenic drug) - OHR Pharmaceutical
    • 10.4.6 Tandospirone (serotonin 1A agonist) - Alcon (Novartis)
    • 10.4.7 UF-021 (unoprostone) - R-Tech Ueno
  • 10.5 Drugs In Phase 2 Development For Retinal Disorders
    • 10.5.1 AKB-9778 (Tie2 activator) - Aerpio Therapeutics
    • 10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
    • 10.5.3 AGN208397 (beclomethasone) - Allergan
    • 10.5.4 CPC 551 - Colby Pharmaceutical
    • 10.5.5 ESBA1008 (anti-VEGF mAb) - Alcon (Novartis)
    • 10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
    • 10.5.7 LFG316 (anti-C5 mAb) - Novartis
    • 10.5.8 Intravitreal brimonidine implant - Allergan
    • 10.5.9 Optina (danazol) - Ampio Pharmaceuticals
    • 10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer
    • 10.5.11 Premiplex (SHP-607) - Shire
    • 10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech
    • 10.5.13 Zybrestat (fosbretabulin) - Oxigene/Symphony VIDA
  • 10.6 Drugs In Phase 1 and Pre-clinical Development for Retinal Disorders
    • 10.6.1 BDM-E - BioDiem
    • 10.6.2 NADPH Oxidase Inhibitors - Alimera Sciences
    • 10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica
    • 10.6.4 Plasma Kallikrein Inhibitors (KVD001) - KalVista
    • 10.6.5 QLT091001 (synthetic retinoid) - QLT
  • 10.7 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2016
  • 10.8 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
    • 10.8.1 EGP-437 (dexamethasone) - EyeGate Pharmaceuticals
    • 10.8.2 IBI-10090 and IBI-20089 - Icon Bioscience
    • 10.8.3 KPI-121 (loteprednol etabonate) - Kala
  • 10.9 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
    • 10.9.1 CF101 (adenosine A3 receptor agonist) - Can-Fite BioPharma and OphthaliX
    • 10.9.2 FST-100 (povidone-iodine/dexamethasone) - Shire
    • 10.9.3 NVC-422 (auriclosene) - NovaBay
    • 10.9.4 Sarilumab - Regeneron
  • 10.10 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
    • 10.10.1 Finafloxacin - MerLion Pharmaceuticals/Novartis
  • 10.11 Drugs For Glaucoma: Development Pipeline, 2016
  • 10.12 Drugs In Phase 2&3 Development For Glaucoma
    • 10.12.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
    • 10.12.2 AMA0076 (ROCK inhibitor) - Amakem
    • 10.12.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) - Aerie Pharmaceuticals
  • 10.13 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
  • 10.14 Drugs For Dry Eye: Development Pipeline, 2016
  • 10.15 Drugs In Phase 3 Development For Dry Eye
    • 10.15.1 EBI-005 (IL-1R antagonist) - Eleven Biotherapeutics
    • 10.15.2 Lifitegrast (integrin antagonist) - Shire
    • 10.15.3 Tavilermide (formerly MIM-D3 tyrosine kinase receptor antagonist) - Allergan
    • 10.15.4 SI-614 (modified hyaluronate) - Seikagaku
  • 10.16 Drugs In Phase 2 Development For Dry Eye
    • 10.16.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
    • 10.16.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
  • 10.17 Other Drugs In The Development Pipeline For Ophthalmic Conditions
    • 10.17.1 Brimonidine For Eye Whitening - Valeant
    • 10.17.2 GS-101 (aganirsen) - Gene Signal
    • 10.17.3 Omidria (phenylephrine/ketorolac) - Omeros

11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2016-2026

  • 11.1 Market Factors Influencing Ophthalmic Drugs
  • 11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
  • 11.3 Strengths
    • 11.3.1 A Healthy R&D Pipeline
    • 11.3.2 Advances In Drug Delivery Technologies
    • 11.3.3 Support For Reimbursement And Payment Approvals
    • 11.3.4 Gene Therapy And RNAi Technology
    • 11.3.5 New Ophthalmic Therapeutic Applications For Drugs
    • 11.3.6 Development Of Neuroprotective Anti-Glaucoma Medications
    • 11.3.7 Biomarkers As Tools For Better Diagnosis And Treatment
  • 11.4 Weaknesses
    • 11.4.1 Low Levels of Patient Adherence To Treatment
    • 11.4.2 High Treatment Burden On Patients And Healthcare Providers
    • 11.4.3 Under-Diagnosis And Under-Treatment
  • 11.5 Opportunities
    • 11.5.1 Sustained-Release Ocular Implants
    • 11.5.2 The Impact Of A Rapidly Ageing Global Population
    • 11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
    • 11.5.4 Glaucoma And Retinal Disorders Set for Most-Marked Increases in Prevalence
    • 11.5.5 Unmet Clinical Need In Many Disease Areas
    • 11.5.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
  • 11.6 Threats
    • 11.6.1 Intensifying Price Regulation In The Market
    • 11.6.2 Generic Competition - Likely to Cause Erosion of Sales for Market Leading Brands
    • 11.6.3 Rising Cost Of R&D
    • 11.6.4 Biosimilars - A Bigger Threat than Generics?
  • 11.7 Porter's Five Force Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
    • 11.7.1 Threat of New Entrants
    • 11.7.2 Rivalry Among Competitors
    • 11.7.3 Power of Suppliers
    • 11.7.4 Threat of Substitutes
    • 11.7.5 Power of Buyers

12. Conclusions

  • 12.1 Overview Of Current Market Conditions And Market Forecast, 2015-2026
  • 12.2 Leading Sectors In Ophthalmic Drugs In 2015
  • 12.3 Leading Regions In The Ophthalmic Drugs Market In 2015
  • 12.4 Leading Companies In The Ophthalmic Drugs Market, 2015
  • 12.5 What Does The Future Hold For Ophthalmic Drugs?

13. Glossary

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2015-2026 (Redacted Data)
  • Table 2.1 ICD 10 Classification of Visual Impairment, 2010
  • Table 2.2 Drug Treatments For Glaucoma, 2016
  • Table 2.3 Drug Treatments For Age-Related Macular Degeneration, 2016
  • Table 2.4 Drug Treatments For Ocular Allergy, 2016
  • Table 2.5 Drug Treatments For Ocular Inflammatory Disease, 2016
  • Table 2.6 Drug Treatments For Eye Infections, 2016
  • Table 2.7 Clinical Trial Phases, 2016
  • Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2015
  • Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2015-2026
  • Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2015-2020, 2020-2026, 2015-2026
  • Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2015, 2020, 2026
  • Table 4.1 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2015
  • Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
  • Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
  • Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR(%) and CAGR(%), 2015-2026
  • Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.1 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2015
  • Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
  • Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
  • Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2015
  • Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
  • Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
  • Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2015
  • Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2015-2026
  • Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2015, 2020, 2026
  • Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2014-2025
  • Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2015-2026
  • Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2015
  • Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2015-2026
  • Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2015-2020, 2020-2026, and 2015-2026
  • Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2015, 2020, and 2026
  • Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.7 The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2015-2026
  • Table 8.8 The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2015
  • Table 8.9 The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.10 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2015, 2020, 2026
  • Table 8.11 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.12 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.13 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.14 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.15 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.16 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.17 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.18 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.19 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.21 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.22 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.23 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.24 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.25 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.26 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.27 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.28 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.29 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.30 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 8.31 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.32 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2015
  • Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2015-2026
  • Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2015, 2020, 2026
  • Table 9.4 Novartis: Company Overview, 2016
  • Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.6 Regeneron: Company Overview, 2016
  • Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.8 Allergan: Company Overview, 2016
  • Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.10 Roche: Company Overview, 2015
  • Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.13 Valeant: Company Overview, 2016
  • Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.15 Santen: Company Overview, 2015
  • Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.17 Bayer: Company Overview, 2015
  • Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.19 Pfizer: Company Overview, 2016
  • Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 9.21 Senju: Company Overview, 2016
  • Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2026
  • Table 10.1 Retinal Disorders Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs, 2016 (continued)
  • Table 10.3 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2016
  • Table 10.4 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2016
  • Table 10.7 Glaucoma Drugs Pipeline: Phase 2&3 Drugs, 2016
  • Table 10.8 Glaucoma Drugs Pipeline: Phase 1 and Pre-clinical Drugs, 2016
  • Table 10.9 Dry Eye Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.10 Dry Eye Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.11 Other Pipeline Products for Ophthalmic Conditions, 2016
  • Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2016-2026
  • Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2015-2026
  • Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases from 2015
  • Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2015, 2020, 2026
  • Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2015, 2020, 2026

List of Figures

  • Acucela
  • Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2016
  • Figure 2.1 Structure Of The Human Eye
  • Figure 2.2 Estimated Global Prevalence Of Visual Impairment (millions of people), 2014
  • Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
  • Figure 2.4 Classification Of Glaucoma, 2016
  • Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2015
  • Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2015-2020
  • Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2020-2026
  • Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2015-2026
  • Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2015
  • Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2020
  • Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2026
  • Figure 4.1 Top Drugs In The Retinal Disorder Drugs Market: Revenue ($m), 2015
  • Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2014-2025
  • Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2015-2026
  • Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2015
  • Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2020
  • Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2026
  • Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2015-2026
  • Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2015-2026
  • Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2015-2026
  • Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2015-2026
  • Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.1 Leading Drugs In The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2015
  • Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2015-2026
  • Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2015
  • Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2020
  • Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2026
  • Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2015-2026
  • Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2015
  • Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2015-2026
  • Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2015
  • Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2020
  • Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2026
  • Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2015-2026
  • Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2015-2026
  • Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2015
  • Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2014-2025
  • Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2015
  • Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2020
  • Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2026
  • Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2015-2026
  • Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2015-2026
  • Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2015-2026
  • Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2015-2026
  • Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2015-2026
  • Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2015-2026
  • Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2015
  • Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2015-2026
  • Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2015-2026
  • Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2015-2020
  • Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2020-2026
  • Figure 8.6 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2015-2026
  • Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2015
  • Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2020
  • Figure 8.9 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2026
  • Figure 8.10 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.11 The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2015
  • Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2015-2026
  • Figure 8.13 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2015
  • Figure 8.14 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2020
  • Figure 8.15 The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2026
  • Figure 8.16 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.18 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.19 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.20 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.21 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.22 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.23 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.24 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.25 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 8.26 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2015-2026
  • Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2015
  • Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%) by Leading Companies, 2015-2026
  • Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2015
  • Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2020
  • Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2026
  • Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2015-2026
  • Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2015-2026
  • Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
  • Figure 11.3 Porter's Five Force Analysis of the Ophthalmic Drugs Market, 2016
  • Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2015, 2020, 2026
  • Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2015-2026

Companies Listed

  • Acucela
  • Actavis
  • Advanced Cell Technologies
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Alcon
  • Alembic
  • Algeta
  • Alimera Sciences
  • Allegro
  • Allergan
  • Akorn
  • Amakem
  • Amgen
  • Ampio Pharmaceuticals
  • Apotex
  • Asahi Glass
  • AstraZeneca
  • Aurobindo Pharma Ltd
  • Aventis
  • Barr Laboratories
  • Bausch & Lomb
  • Biocad
  • BioDiem
  • Biovail Corporation
  • BioXpress Therapeutics
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Cipla
  • Chengdu Kanghong Pharmaceutical
  • Chiesi Farmaceutici S.p.A
  • Chiron Corporation
  • Chugai Pharmaceutical
  • CIBA VISION
  • Colby Pharmaceuticals
  • Daiichi Sankyo
  • Eleven Biotherapeutics
  • Eli Lilly
  • ESBATech
  • EyeCyte
  • EyeGate
  • Eyetech Pharmaceuticals
  • ForeSight Biotherapeutics
  • ForSight VISION4
  • Fougera Pharmaceuticals
  • Gene Signal
  • Genentech
  • GlaxoSmithKline
  • Hospira
  • iCo Therapeutics
  • Icon Bioscience
  • InSite Vision
  • Inspire Pharmaceuticals
  • Instituto Terapeutico Delta Ltda
  • Jenapharm
  • Johnson & Johnson
  • Kala Pharmaceuticals
  • KalVista
  • Kestrel Ophthalmics
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lpath
  • MacuCLEAR
  • MacuSight
  • MAP Pharmaceuticals
  • MEAgate International FZLLC
  • Meda
  • Merck & Co. (Merck)
  • MerLion
  • Molecular Partners
  • MSD K.K.
  • Neurim Pharmaceuticals
  • Neurotech
  • NovaBay
  • Novagali
  • Novartis
  • Novel Labs Inc
  • OHR Pharmaceutical
  • Omeros
  • OphthaliX
  • Ophthotech
  • PanOptica
  • Patheon Pharmaceuticals
  • Par Pharmaceutical
  • Pfizer
  • Pharmacia
  • PreCision Dermatology
  • Procter & Gamble
  • pSivida
  • QLT
  • Quark Pharmaceuticals
  • Regeneron
  • Reckitt Benckiser
  • Roche
  • Roche Consumer Health
  • R-Tech Ueno
  • RXi Pharmaceuticals
  • Salix
  • Sanofi
  • Sandoz
  • Santaris Pharma
  • Santen
  • Schering AG
  • Seikagaku
  • Senju
  • Servier
  • Shire
  • SkinMedica
  • Sobi
  • Stelgerwald
  • Spark Therapeutics
  • Takeda
  • ThromboGenics
  • Upjohn
  • UV North America
  • Valeant
  • Vanda Pharmaceuticals
  • Ventana Medical Systems
  • Warburg Pincus LLC
  • Watson
  • Wockhardt
  • Wyeth Pharmaceuticals
  • Zach System Spa

Organisations Mentioned in the Report

  • A*STAR Institute for Infocomm Research (Singapore)
  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Australian Therapeutic Goods Administration
  • Emory University
  • European Medicines Agency (EMA)
  • Health Canada
  • Italian National Health Service
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • Japan Patent Office
  • Johns Hopkins University (Baltimore, US)
  • National Institute of Clinical Excellence (NICE)
  • National Institute of Health (NIH)
  • Ophthalmic Drugs Advisory Committee - Division of the FDA
  • Portsmouth Primary Care Trust
  • Tokyo University of Science
  • UK National Health Service (NHS)
  • United Nations Department of Economic and Social Affairs, Population Division
  • University of Modena and Reggio Emilia
  • US Food and Drug Agency (FDA)
  • US National Eye Institute (NEI)
  • US Preventive Services Task Force
  • World Health Organization (WHO)
Back to Top